NAMPT was identified as a promising anticancer target due to the absence of other NAD+ synthesis enzymes in several tumors (e.g., prostate carcinoma, sarcomas, neuroblastomas and glioblastomas) [21,22,23], its association with worse prognosis in glioblastomas [24] and its overexpression in several types of tumor cells including gliomas [25]. The gene discussed is NAMPT; the disease is glioma.